Change of Director's Interest Notices x 4

Aug 27, 2026 at 12:50 AM EDT · Issued by Radiopharm Theranostics Limited via ASX

Filed with ASX · Aug 27, 2026 at 12:50 AM EDT

On 6ix: 6ix.com/news/change-of-directors-interest-notices-x-4-7

Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. ...

View Attachment

6ix hasn’t read this filing yet.

Radiopharm Theranostics Limited on 6ix

Earlier from Radiopharm Theranostics

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid TumorsAug 26
RAD Doses First Patient in Second Cohort of BetaBart (RV-01)Aug 25
Ceasing to be a substantial holderAug 24
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical TrialAug 20
RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT TrialAug 19

Later from Radiopharm Theranostics

Appendix 4E and Preliminary Final ReportAug 28
RAD Announces Positive Data from RAD301 P1 Imaging TrialSep 8
Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal AdenocarcinomaSep 9
Results of MeetingSep 10
RAD oral presentation at SNO26 on RAD101 Phase IIb dataSep 13

All Radiopharm Theranostics news releases

Follow Radiopharm Theranostics into a list and get an email when it puts out news.

Follow Radiopharm Theranostics